Guerbet appoints Yves L'Epine CEO
This article was originally published in Scrip
Guerbet, a pharmaceutical group dedicated to medical imaging, has appointed Dr Yves L'Epine CEO, following the death of the company's former CEO, Bernard Massiot, in May 2011. Dr L'Epine will take up his position at the end of November, and has previously held general management roles at Novartis, Takeda and Abbott.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.